HT 003
Alternative Names: alpha muteinLatest Information Update: 25 Sep 2021
At a glance
- Originator Han Il
- Class Anti-inflammatories; Antineoplastics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Sep 1998 Profile reviewed
- 08 Sep 1998 No-Development-Reported for Cancer in South Korea (Unknown route)
- 29 Aug 1996 Preclinical development for Cancer in South Korea (Unknown route)